Immunization information systems to increase vaccination rates: costs analysis

Added June 9, 2020

Citation: Patel M, Pabst L, Chattopadhyay S, et al. The Community Preventive Services Task force. Economic review of immunization information systems to increase vaccination rates: a community guide systematic review. Journal of Public Health Management and Practice 2015; 21(3): 253‐262

What is this? The COVID-19 pandemic has placed a strain on healthcare services and resources. Existing evidence on the cost effective delivery of health care, such as immunizations might provide useful information for policy makers.

In this systematic review, the authors searched for evaluations of the cost and benefits of implementing, operating and participating with an immunization information system (IIS). They restricted their search to articles published since January 1994 and did the search in March 2012. They included 12 published articles and 2 government reports were identified, all of which assessed IIS in the USA and focused on paediatric immunizations.

What was found: The systems evaluated in the included studies are outdated, making the evidence potentially less relevant to current IIS, but the benefit to cost ratio should not be any less favourable.

Costs per child ranged from US$5.40 to US$60.82 and costs per vaccination record ranged from US$0.11 to US$12.88. Variability in costs might be attributable to the scale of the IIS and the target population size

Benefit analysis from 9 studies comparing administrative benefits versus manually performed vaccination related activities showed savings from using IIS.

The economic benefits that result from reduced morbidity and mortality from vaccine preventable diseases are uncertain.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.